Literature DB >> 27287265

Alport Syndrome in Women and Girls.

Judy Savige1, Deb Colville2, Michelle Rheault3, Susie Gear4, Rachel Lennon5, Sharon Lagas6, Moira Finlay7, Frances Flinter8.   

Abstract

Alport syndrome is an inherited disease characterized by progressive renal failure, hearing loss, and ocular abnormalities. Inheritance is X-linked (85%) or autosomal recessive (15%). Many renal physicians think of Alport syndrome as primarily affecting men. However, twice as many women are affected by the X-linked diseases. Affected women are commonly undiagnosed, but 15%-30% develop renal failure by 60 years and often hearing loss by middle age. Half of their sons and daughters are also affected. Autosomal recessive Alport syndrome is less common, but is often mistaken for X-linked disease. Recessive inheritance is suspected where women develop early-onset renal failure or lenticonus. Their family may be consanguineous. The prognosis for other family members is very different from X-linked disease. Other generations, including parents and offspring, are not affected, and on average only one in four of their siblings inherit the disease. All women with Alport syndrome should have their diagnosis confirmed with genetic testing, even if their renal function is normal, because of their own risk of renal failure and the risk to their offspring. Their mutations indicate the mode of inheritance and the likelihood of disease transmission to their children, and the mutation type suggests the renal prognosis for both X-linked and recessive disease. Women with X-linked Alport syndrome should be tested at least annually for albuminuria and hypertension. The "Expert guidelines for the diagnosis and management of Alport syndrome" recommend treating those with albuminuria with renin-angiotensin-aldosterone system (RAAS) blockade (and adequate birth control because of the teratogenic risks of angiotensin converting enzyme inhibitors), believing that this will delay renal failure. Current recommendations are that women with autosomal recessive Alport syndrome should be treated with RAAS blockade from the time of diagnosis. In addition, women should be offered genetic counseling, informed of their reproductive options, and monitored closely during pregnancy for the development of hypertension.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  ACE inhibitors; Alport syndrome; Chronic; Deafness; Female; Genetic Testing; Hearing Loss; Hereditary; Humans; Kidney Failure; Mutation; Nephritis; albuminuria; genetic renal disease

Mesh:

Year:  2016        PMID: 27287265      PMCID: PMC5012472          DOI: 10.2215/CJN.00580116

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  38 in total

Review 1.  Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females.

Authors:  Clifford E Kashtan
Journal:  Nephrol Dial Transplant       Date:  2007-03-29       Impact factor: 5.992

Review 2.  Use and misuse of preimplantation genetic testing.

Authors:  Peter Braude; Frances Flinter
Journal:  BMJ       Date:  2007-09-06

Review 3.  Pregnancy in advanced chronic kidney disease and end-stage renal disease.

Authors:  Ahd Alkhunaizi; Nir Melamed; Michelle A Hladunewich
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

4.  Alport's syndrome: experience at Hôpital Necker.

Authors:  R Habib; M C Gubler; N Hinglais; L H Noël; D Droz; M Levy; P Mahieu; J M Foidart; D Perrin; E Bois; J P Grünfeld
Journal:  Kidney Int Suppl       Date:  1982-05       Impact factor: 10.545

5.  Aortic abnormalities in males with Alport syndrome.

Authors:  Clifford E Kashtan; Yoav Segal; Frances Flinter; David Makanjuola; Jay-Sen Gan; Terry Watnick
Journal:  Nephrol Dial Transplant       Date:  2010-05-21       Impact factor: 5.992

Review 6.  Familial hematuria.

Authors:  Clifford E Kashtan
Journal:  Pediatr Nephrol       Date:  2007-10-02       Impact factor: 3.714

7.  Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling.

Authors:  Oliver Gross; Kai-Olaf Netzer; Romy Lambrecht; Stefan Seibold; Manfred Weber
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

8.  Alport syndrome and diffuse leiomyomatosis: deletions in the 5' end of the COL4A5 collagen gene.

Authors:  C Antignac; J Zhou; M Sanak; P Cochat; B Roussel; G Deschênes; F Gros; B Knebelmann; M C Hors-Cayla; K Tryggvason
Journal:  Kidney Int       Date:  1992-11       Impact factor: 10.612

9.  Stability related bias in residues replacing glycines within the collagen triple helix (Gly-Xaa-Yaa) in inherited connective tissue disorders.

Authors:  Anton V Persikov; Rian J Pillitteri; Priyal Amin; Ulrike Schwarze; Peter H Byers; Barbara Brodsky
Journal:  Hum Mutat       Date:  2004-10       Impact factor: 4.878

10.  Evidence of digenic inheritance in Alport syndrome.

Authors:  Maria Antonietta Mencarelli; Laurence Heidet; Helen Storey; Michel van Geel; Bertrand Knebelmann; Chiara Fallerini; Nunzia Miglietti; Maria Fatima Antonucci; Francesco Cetta; John A Sayer; Arthur van den Wijngaard; Shu Yau; Francesca Mari; Mirella Bruttini; Francesca Ariani; Karin Dahan; Bert Smeets; Corinne Antignac; Frances Flinter; Alessandra Renieri
Journal:  J Med Genet       Date:  2015-01-09       Impact factor: 6.318

View more
  37 in total

1.  Autosomal Recessive Alport Syndrome Unveiled by Pregnancy.

Authors:  Erika R Drury; Isaac E Stillman; Martin R Pollak; Bradley M Denker
Journal:  Nephron       Date:  2019-08-13       Impact factor: 2.847

2.  Alport syndrome: deducing the mode of inheritance from the presence of haematuria in family members.

Authors:  Judy Savige
Journal:  Pediatr Nephrol       Date:  2018-11-30       Impact factor: 3.714

3.  Functional assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in X-linked Alport syndrome.

Authors:  Andrew F Malone; Steven D Funk; Tarek Alhamad; Jeffrey H Miner
Journal:  Pediatr Nephrol       Date:  2016-12-24       Impact factor: 3.714

4.  Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS.

Authors:  Tony Yao; Khalil Udwan; Rohan John; Akanchaya Rana; Amirreza Haghighi; Lizhen Xu; Saidah Hack; Heather N Reich; Michelle Adrienne Hladunewich; Daniel C Cattran; Andrew D Paterson; York Pei; Moumita Barua
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-15       Impact factor: 8.237

Review 5.  Genomic medicine for kidney disease.

Authors:  Emily E Groopman; Hila Milo Rasouly; Ali G Gharavi
Journal:  Nat Rev Nephrol       Date:  2018-01-08       Impact factor: 28.314

Review 6.  Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane.

Authors:  Steven D Funk; Meei-Hua Lin; Jeffrey H Miner
Journal:  Matrix Biol       Date:  2018-04-16       Impact factor: 11.583

7.  De novo X-linked Alport syndrome in a 3-year-old girl.

Authors:  Hiroshi Komatsu; Takeshi Goda; Kandai Nozu
Journal:  BMJ Case Rep       Date:  2019-07-15

Review 8.  Rare genetic causes of complex kidney and urological diseases.

Authors:  Emily E Groopman; Gundula Povysil; David B Goldstein; Ali G Gharavi
Journal:  Nat Rev Nephrol       Date:  2020-08-17       Impact factor: 28.314

Review 9.  Expert consensus guidelines for the genetic diagnosis of Alport syndrome.

Authors:  Judy Savige; Francesca Ariani; Francesca Mari; Mirella Bruttini; Alessandra Renieri; Oliver Gross; Constantinos Deltas; Frances Flinter; Jie Ding; Daniel P Gale; Mato Nagel; Michael Yau; Lev Shagam; Roser Torra; Elisabet Ars; Julia Hoefele; Guido Garosi; Helen Storey
Journal:  Pediatr Nephrol       Date:  2018-07-09       Impact factor: 3.714

Review 10.  Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.

Authors:  Annalisa Giandalia; Alfio Edoardo Giuffrida; Guido Gembillo; Domenico Cucinotta; Giovanni Squadrito; Domenico Santoro; Giuseppina T Russo
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.